CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.38
-0.02 (-0.37%)
At close: Jun 27, 2025, 4:00 PM
5.40
+0.02 (0.37%)
After-hours: Jun 27, 2025, 6:59 PM EDT
CureVac Stock Forecast
Stock Price Forecast
The 3 analysts that cover CureVac stock have a consensus rating of "Hold" and an average price target of $6.83, which forecasts a 26.95% increase in the stock price over the next year. The lowest target is $5 and the highest is $10.
Price Target: $6.83 (+26.95%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for CureVac stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $12 → $5.5 | Strong Buy → Hold | Downgrades | $12 → $5.5 | +2.23% | Jun 26, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $7 → $5 | Strong Buy → Hold | Downgrades | $7 → $5 | -7.06% | Jun 13, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $10 | Buy | Reiterates | $10 | +85.87% | May 28, 2025 |
| UBS | UBS | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +123.05% | Apr 30, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $16 | Buy | Reiterates | $16 | +197.40% | Feb 14, 2025 |
Financial Forecast
Revenue This Year
70.41M
from 535.18M
Decreased by -86.84%
Revenue Next Year
87.33M
from 70.41M
Increased by 24.04%
EPS This Year
-0.54
from 0.72
EPS Next Year
-0.51
from -0.54
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 133.6M | 166.5M | 210.7M | ||
| Avg | 70.4M | 87.3M | 143.4M | ||
| Low | 882,000 | n/a | 78.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -75.0% | 136.4% | 141.2% | ||
| Avg | -86.8% | 24.0% | 64.2% | ||
| Low | -99.8% | - | -9.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.27 | -0.25 | 0.19 |
| Avg | -0.54 | -0.51 | -0.27 |
| Low | -0.73 | -0.77 | -0.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.